A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies

Summary

This is a phase I, multicenter, open label, sequential-cohort, dose escalation study of ESG206. The purpose is to evaluate the clinical safety, tolerability, PK (pharmacokinetics), and preliminary efficacy and to establish the MTD (maximum tolerated dose), if any, and RP2D (recommended phaseII dose) of ESG206 in adult subjects with B lymphoid malignancies.

Timeline

Start

2023-08-02

Primary completion

2025-01-22

Completion

2025-01-22

Drugs

Indications